Administer imeglimin hydrochloride orally as a film-coated tablet, typically at a dosage of 1000 mg twice daily. The tablets should be taken with meals to manage glycemic control in adults with Diabetes Mellitus Type 2. Patients should swallow the tablets whole and avoid crushing or chewing them. While no dose adjustment is generally required for mild renal impairment, administration is not recommended for patients with moderate to severe renal impairment, specifically those with an estimated glomerular filtration rate (eGFR) less than 45 mL/min/1.73 m2, due to increased plasma concentrations. Regular monitoring of renal function is advised before and during treatment. The safety and efficacy of imeglimin have not been established in pediatric populations or those with significant hepatic dysfunction.

Details coming soon